Navigation Links
Unigene's Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
Date:11/30/2011

ise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements, including with respect to clinical studies of one of our licensees. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securit
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
5. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
6. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
7. Nventa Develops Proprietary Vaccine Adjuvant
8. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
11. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 Today, iHealth Lab Inc. announced ... Ventures, Ltd. for its first institutional round of funding. ... iHealth,s global reach, accelerate growth and innovation, and invest ... the investment, Xiaomi Ventures will join iHealth,s board of ... infrastructure and ecommerce. "We are very pleased ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... Calif., April 14 Researchers at,the Barbara ... been studying,racial disparities related to cancer patients. ... (AACR) Annual Meeting, Karmanos researchers,Vitaly Balan, Ph.D., ... their abstract, Galectin-3 nsSNP rs4644 Foretells Human ...
... 14 Perrigo Company,(Nasdaq: PRGO ; ... final approval,from the U.S. Food and Drug ... Cetirizine Hydrochloride Oral Solution,(Allergy) and Children,s Cetirizine ... will be marketed under store brand labels ...
Cached Medicine Technology:Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 2Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women 3Perrigo Announces Approval for Over-the-Counter Children's Cetirizine Oral Solution 2
(Date:9/19/2014)... leading Dartmouth researcher, working with The Melanoma Genetics Consortium, ... today in the Journal of the National Cancer ... of melanoma. , "For the first time, we have ... telomeres play a part in the risk of developing ... PhD, School of Medicine at the University of Leeds ...
(Date:9/19/2014)... News) -- U.S. military troops deployed to sunny climates ... to a new study. Many returning troops ... some cases, military personnel developed blisters on their skin ... size of their moles since being deployed overseas. ... skin cancer, the study authors noted. "The past ...
(Date:9/19/2014)... The U.S. Food and Drug Administration approved a new type ... a class of once-a-week injectable drugs that help manage blood ... "Trulicity is a new treatment option, which can be used ... sugar levels in the overall management of type 2 diabetes," ... Drug Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... 2014 MetroMD, a leading anti-ageing clinic has ... of human health. This therapy has grown tremendously across USA ... more effective, safe and dependable. It has far reaching benefits ... to live a very healthy and active lifestyle even beyond ... therapy, a senior therapist at MetroMD said, “HGH or Human ...
(Date:9/19/2014)... - New research published today in the online journal ... reach 6,800 in West Africa by the end of ... , Arizona State University and Harvard University researchers ... rise in cases significantly increased in August in Liberia ... was put in place, indicating that the mass quarantine ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2
... April 2010 - Elsevier, the world-leading publisher of ... proudly announces the release of a brand-new single ... mitral valve disease by the internationally renowned cardiac ... will launch at the 90th Annual Meeting of ...
... ... and printing products, today announced it is ready for immediate shipping of thousands of ... through customer service or instantly online from the company’s award winning web site My1Stop.com. ... Ft. Scott, ...
... ... money with FatWallet’s expert selection of deals for Mother’s Day. Experienced experts research the ... and seasonal categories such as laptops, HDTVs, Father’s Day and graduation. , ... (PRWEB) April 26, 2010 -- ...
... ... Documentation by Integrating Electronic Medical Forms Generated During the Pre-operative Process into Core ... ... important new level of clinical integration designed to provide immediate access to patient ...
... ... area residents safe and effective cosmetic and aesthetic treatments. Advanced Aesthetics utilizes top ... ... The art of aesthetics is continually changing. As technology progresses, innovative treatments replace ...
... that factors known to increase the risk of breast cancer ... Published early online in Cancer , a peer-reviewed journal ... is needed to evaluate how breast cancer risk factors differ ... frequently in certain ethnic and racial groups, but the reasons ...
Cached Medicine News:Health News:Elsevier launches Carpentier's reconstructive valve surgery book 2Health News:My1Stop.com New Packaging Supplies Offering for Distribution Centers and Small Business Shipping 2Health News:Expert Approved: FatWallet Guides Mother's Day Shoppers to the Best Deals Online 2Health News:SourceMedical Provides Ambulatory Surgery Centers with New Levels of Document Integration for Easy Access to Patient Data 2Health News:SourceMedical Provides Ambulatory Surgery Centers with New Levels of Document Integration for Easy Access to Patient Data 3Health News:In Coeur d'Alene Idaho, Top Of The Line Aesthetic Treatments And Non-Invasive Laser Technology Can Be Found Only At Advanced Aesthetics 2Health News:In Coeur d'Alene Idaho, Top Of The Line Aesthetic Treatments And Non-Invasive Laser Technology Can Be Found Only At Advanced Aesthetics 3Health News:Breast cancer risk factors differ among races 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
Medicine Products: